Evidence map›Paper›PMID 22539965›Full record

ArticlePloS one2012

Sulforaphane potentiates RNA damage induced by different xenobiotics.

Carmela Fimognari, Monia Lenzi, Piero Sestili, Eleonora Turrini, Lorenzo Ferruzzi, Patrizia Hrelia, Giorgio Cantelli-Forti

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Role of Oxidative RNA Damage in Chronic-Degenerative Diseases.Oxidative medicine and cellular longevity · 2015
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Carmela FimognariDepartment of Pharmacology, Alma Mater Studiorum - University of Bologna, Bologna, Italy. carmela.fimognari@unibo.it
Monia Lenzi
Piero Sestili
Eleonora Turrini
Lorenzo Ferruzzi
Patrizia Hrelia
Giorgio Cantelli-Forti
University of Bologna · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe isothiocyanate sulforaphane (SFN) possesses interesting anticancer activities. However, recent studies reported that SFN promotes the formation of reactive oxygen species (ROS) as well as DNA breakage. METHODOLOGY/PRINCIPAL

findingsWe investigated whether SFN is able to damage RNA, whose loss of integrity was demonstrated in different chronic diseases. Considering the ability of SFN to protect from genotoxicity, we also examined whether SFN is able to protect from RNA damage induced by different chemicals (doxorubicin, spermine, S-nitroso-N-acetylpenicillamine, H(2)O(2)). We observed that SFN was devoid of either RNA damaging and RNA protective activity in human leukemic cells. It was able to potentiate the RNA damage by doxorubicin and spermine. In the first case, the effect was attributable to its ability of modulating the bioreductive activation of doxorubicin. For spermine, the effects were mainly due to its modulation of ROS levels produced by spermine metabolism. As to the cytotoxic relevance of the RNA damage, we found that the treatment of cells with a mixture of spermine or doxorubicin plus SFN increased their proapoptotic potential. Thus it is conceivable that the presence of RNA damage might concur to the overall toxic response induced by a chemical agent in targeted cells. CONCLUSIONS/SIGNIFICANCE: Since RNA is emerging as a potential target for anticancer drugs, its ability to enhance spermine- and doxorubicin-induced RNA damage and cytotoxicity could represent an additional mechanism for the potentiating effects of SFN associated with anticancer drugs.

Indexed as

Antineoplastic AgentsCell Line, TumorCell SurvivalDNA DamageHL-60 CellsHumansIsothiocyanatesJurkat CellsReactive Oxygen SpeciesRNASpermineSulfoxidesThiocyanatesThioredoxin-Disulfide ReductaseXenobioticsAntineoplastic AgentsIsothiocyanatesReactive Oxygen SpeciesRNASperminesulforaphaneSulfoxidesThiocyanatesThioredoxin-Disulfide ReductaseXenobiotics

Identifiers

PMID22539965
PMCPMC3335137
OpenAlexW2017514599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.